Penile TPF

A Phase II non-randomised multicentre trial of docetaxel, cisplatin & 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis. 26 evaluable patients recruited to receive Docetaxel 75mg/m2 day 1, cisplatin 60mg/m2 day 1, 5-fluorouracil 750mg/m2/day (day 1-5), peated at intervals of 21 days. The primary endpoint, measured by RECIST v1, (complete remission rate + partial remission rate). Secondary endpoints are te proportion of patients with inoperable locoregional disease rendered operable by TPF chemotherapy, progression-free survival, overall survival, acute toxicity (as determined by CTCAE) after each cycle and at 3 months and late toxicity (CTCAE). Formalin fixed paraffin embedded tissue samples are held at the Orchid Research Tissue Bank at Barts and the London School of Medicine and Dentistry.

Existing samples:

  • Malignant tumor of penis (disorder)

Contact Information

Email:
peniletpf-icrctsu@icr.ac.uk
Address:

Orchid Research Tissue Bank
John Vane Science Centre
Charterhouse Square
London
Middlesex
EC1M 6BQ
UK

Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A